> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bridge Biotherapeutics Given Orphan Designation for BBT-877
- URL: https://www.fdaweb.com/bridge-biotherapeutics-given-orphan-designation-for-bbt-877/
- Published: 2019-01-17T12:00:00.000Z
- Updated: 2026-09-15T00:55:05.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5143179

FDA has granted Bridge Biotherapeutics an orphan drug designation for BBT-877, an autotaxin inhibitor that deregulates ATX, an enzyme found to be associated with inflammation and fibrosis. The early-stage compound of BBT-877 had been originally discovered by LegoChem Biosciences and Bridge Biotherapeutics acquired the worldwide exclusive rights in 2017.

Bridge says it will begin a Phase 1 study of BBT-877 in the U.S. next month to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the drug candidate in healthy volunteers. The planned study will be in two phases, a single ascending dose phase with five cohorts and a multi ascending dose phase with three cohorts.